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Purpose: Quantitative analysis of CT scans has proven to be a reproducible technique, which
might help to understand the pathophysiology of chronic obstructive pulmonary disease (COPD)
and combined pulmonary ﬁbrosis and emphysema. The aim of this retrospective study was to ﬁnd
out if the lung function of patients with COPDwith Global Initiative for Chronic Obstructive Lung
Disease (GOLD) stages III or IV and pulmonary emphysema is measurably inﬂuenced by high
attenuation areas as a correlate of concomitant unspeciﬁc ﬁbrotic changes of lung parenchyma.
Patients and methods: Eighty-eight patients with COPD GOLD stage III or IV underwent
CT and pulmonary function tests. Quantitative CT analysis was performed to determine low
attenuation volume (LAV) and high attenuation volume (HAV), which are considered to be
equivalents of ﬁbrotic (HAV) and emphysematous (LAV) changes of lung parenchyma. Both
parameters were determined for the whole lung, as well as peripheral and central lung areas only.
Multivariate regression analysis was used to correlate HAV with different parameters of lung
function.
Results: Unlike LAV, HAV did not show signiﬁcant correlation with parameters of lung
function. Even in patients with a relatively high HAVof more than 10%, in contrast to HAV
(p=0.786) only LAV showed a signiﬁcantly negative correlation with forced expiratory
volume in 1 second (r=−0.309, R2=0.096, p=0.003). A severe decrease of DLCO% was
associated with both larger HAV (p=0.045) and larger LAV (p=0.001). Residual volume and
FVC were not inﬂuenced by LAV or HAV.
Conclusion: In patients with COPD GOLD stage III-IV, emphysematous changes of lung
parenchyma seem to have such a strong inﬂuence on lung function, which is a possible effect
of concomitant unspeciﬁc ﬁbrosis is overwhelmed.
Keywords: COPD, quantitative CT, pulmonary ﬁbrosis, pulmonary emphysema, CPFE
Introduction
Chronic obstructive pulmonary disease (COPD) has high morbidity and mortal-
ity and is the fourth leading cause of death in the world.1 Patients typically
present with decreased lung function, caused by hyperinﬂation and reduced gas
exchange.
Chronic pulmonary inﬂammation histologically results in irreversible destruc-
tion and dilatation of terminal air spaces, chronic bronchiolitis, and variable ﬁbrotic
changes of the smaller airways. These structural alterations lead to decreased gas
exchange, airﬂow limitation, and air trapping. Lung function tests typically show a
reduced forced expiratory volume in one second (FEV1), an increased total lung
volume, and a decreased FEV1/functional vital capacity (FVC)-ratio.2,3
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High-resolution computed tomography (HRCT) imaging
often shows a typical pattern of centrilobular emphysema.
The COPD Gene Study Group and other investigators
reported concomitant interstitial pulmonary abnormalities
with higher attenuation on CT scans (ie, ground-glass, reti-
cular, and nodular opacities) in a large number of patients
with COPD.4,5 More severe and characteristic ﬁbrotic
changes in combination with emphysema are summarized
in the entity of combined pulmonary ﬁbrosis and emphy-
sema (CPFE), ﬁrst described in 1974. Auerbach et al,
coined the term CPFE to describe a distinct entity, exhibit-
ing more severe ﬁbrotic changes in conjunction with
emphysema.5 CPFE is characterized by upper lobe emphy-
sema and predominantly lower lobe ﬁbrosis with honey-
combing, bronchiectasis, and other ﬁndings of a usual
interstitial pneumonia (UIP)-pattern.6,7 In addition to these
well-deﬁned HRCT-ﬁndings, the COPD Gene Study Group
demonstrated a high prevalence of unspeciﬁc interstitial
shadowing and interstitial pneumonia in patients with
COPD.4 Washko et al, described interstitial lung abnormal-
ities in smokers in about 1 of every 12 HRCT scans and an
association with reduced total lung capacity (TLC) and a
lesser amount of emphysema.8 Chronic ﬁbrotic patterns due
to smoking can occur in three distinct entities; non-speciﬁc
interstitial pneumonia (NSIP), smoking-related interstitial
pneumonia, and UIP.9,10
For COPD and CPFE, qualitative and quantitative
HRCT-measures of TLC (total volume or percentage of
expected lung volume) and the extent of emphysema
(threshold-based identiﬁcation of low attenuation areas
(LAA)) are well described.4,11–15 Recent studies compared
HRCT-ﬁndings with clinical symptoms in an attempt to
identify correlations between CT-metrics and parameters
of pulmonary function. Ando et al, found ﬁbrotic lesions
to predict progression of CPFE better than emphysematous
changes did.15 These ﬁndings were corroborated by Choi
et al, who also identiﬁed the severity of ﬁbrosis to be an
important prognostic factor.16 In CPFE, there is evidence
of a counterbalancing effect between restrictive and
obstructive pathomechanisms, resulting from traction of
the smaller airways and hyperinﬂation due to emphysema.
Because of this effect, FEV1, forced vital capacity (FVC),
residual volume (RV), and TLC are within relatively nor-
mal ranges in most patients with CPFE.6,17–19 Kitaguchi et
al, showed a less marked decrease of FEV1 in patients
with CPFE, compared with a group of patients with
emphysema only.20 Another trial evaluating 2,416
HRCT-scans of smokers found a lower TLC and a lower
percentage of emphysema in patients with interstitial lung
abnormalities.21
Few studies investigated possible associations between
high attenuation volumes (HAV, also referred to as high-
attenuation areas, HAA) and clinical parameters of lung
function. We used HAV, deﬁned by a threshold, as a
parameter potentially representing ﬁbrotic pulmonary
changes, as suggested by several recent studies.4,21–24
Main purpose of the study was to investigate, whether
incidental ﬁbrotic changes, represented by HAA in quan-
titative CT analysis, have a measurable inﬂuence on lung
function (especially FEV1%) in patients with COPD glo-
bal initiative for chronic obstructive lung disease (GOLD)
stages III or IV and pulmonary emphysema.
The results could be helpful for the (COPD) clinician
to better classify CT morphological, ﬁbrotic changes in
COPD patients and, if necessary, also to set the therapy
focus differently. Furthermore, the impact of fast-acting
bronchodilators on correlation studies of quantitative CT
and functional parameters could be of clinical beneﬁt.
Materials and methods
The study was approved by the local ethics committee/
institutional review board (IRB; Charité Ethikkommission;
Entscheid EA1/213/16). Patient consent to anonymously
and retrospectively review their medical records was not
required by IRB due to retrospective analysis. The con-
ﬁdential and anonymous evaluation of the patient data was
guaranteed. The study was conducted in accordance with
the Declaration of Helsinki.
Patients
In this retrospective study, 88 consecutive patients (Table 1)
with COPD and pulmonary emphysema (all with clinical
diagnosis of GOLD stages III or IV) underwent non-contrast
multidetector CT scanning and pulmonary function testing.
All patients with diagnosed or suspected pulmonary ﬁbrosis
(in accordance with IPF guidelines),25 other active lung dis-
ease such as acute exacerbation of COPD, pneumothorax,
pleural effusion, extensive ground-glass opacities, suspicious
nodules, lung tumors, relevant atelectasis or major scars was
excluded from the study after retrospective revision of all CT
images by two blinded thorax radiologists.
CT scans
All CT examinations were performed using the same pro-
tocol (two scans of the whole lung in full inspiratory and
expiratory breathhold) with standardized scanning
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parameters (1.25 mm slice thickness, 120 kV voltage, 100
mA tube current, soft tissue kernel). Quantitative analysis
of the CT datasets was performed with the dedicated soft-
ware tool MeVisPULMO 3D (v3.42, Fraunhofer MEVIS,
Bremen, Germany) to determine volumes of low attenua-
tion volume (LAV) and high attenuation volume (HAV),
deﬁned by a threshold (LAV: <–950 HU; HAV: >–700
HU) as described in previous studies.21,22,26,27 The
MeVisPULMO 3D software package enables quantiﬁca-
tion of emphysematous lung parenchyma by calculating a
pixel index as described by Kuhnigk et al28. HAV is
assumed to represent and allow quantiﬁcation of ﬁbrotic
changes of lung parenchyma. Patients were stratiﬁed into
three groups, based on the magnitude of HAV (<7%, 7–
10%, >10% of lung volume). HAV and LAV were calcu-
lated for the whole lung, central and peripheral volumes,
deﬁned as the volume within a subpleural margin of 2 cm.
Central and peripheral volumes were automatically sepa-
rated by the software tool we used.
In subgroups, attempts were made to conﬁrm the
results of the analyses of global and core/peel volumes.
For this purpose, the effects of HAV were tested on sub-
groups with very low and very high percentage of LAV.
Additionally, in order to evaluate the impact of HAV and
LAV on gradient elastance and/or air trapping, we deter-
mined the respective lung lobe with the highest and lowest
HAV and correlated both HAV and LAV, respectively, with
volume difference between inspiration and expiration.
Lobes were the smallest evaluable subdivision of the
lung parenchyma.
Statistics
Results for HAV and LAV were correlated with different
functional lung parameters that were measured before and
after administration of a fast-acting bronchodilator (pre/
post BS): FEV1% (FEV1= forced expiratory volume in 1
second, percentage of the predicted FEV), functional vital
capacity (FVC), RV, and predicted diffusing capacity of
the lung for carbon monoxide (DLCO%). Multivariate and
simple linear regression analyses as well as subgroup
analyses were performed. Statistical analysis was per-
formed using IBM SPSS Statistics v25 (IBM
Corporation, Armonk, NY, USA). p-values of less than
0.05 were considered to indicate statistical signiﬁcance.
Results
Patient characteristics
Of 88 patients, 35 (43%) were women. Average age was
66.1 (SD 6.6) years with a range of 45–79 years. All
patients fulﬁlled the clinical criteria for COPD GOLD
stages III and IV. FEV1% (measured before and after
application of a bronchodilator) ranged from 13% to
50% (mean 28.8%, SD 8.1, Table 1). Two patients refused
to take a fast-acting bronchodilator; therefore, only n=86
patients were evaluated in the analyses before and after
application of bronchospasmolytic.
Table 1 Characteristics of study subjects
Mean age (years) 66 (SD 6.6; range 45–79)
Male/female sex 53/35 (♀ 43%)
Pack years (n=48) 49 (SD 22)
Forced expiratory volume in 1 second % pre BS (FEV1%, percent of predicted) 27.0 (SD 7.8, range 12–46)
Forced expiratory volume in 1 second % post BS (FEV1%, percent of predicted) 28.8 (SD 8.1, range 13–50)
Total lung capacity % pre BS (TLC, percent of predicted) 123.6 (SD 14.0, range 92–159)
Total lung capacity % post BS (TLC, percent of predicted) 121.8 (SD 14.0, range 87–158)
Residual volume % pre BS (RV, percent of predicted) 222.1 (SD 43.8, range 131–362)
Residual volume % post BS (RV, percent of predicted) 213.2 (SD 42.7, range 92–316)
Functional vital capacity % pre BS (FVC, percent of predicted) 65.1 (SD 15.7, range 36–120)
Functional vital capacity % post BS (FVC, percent of predicted) 69 (SD 15.8, range 38–112)
Diffusing capacity of the lung for carbon monoxide % (DLCO, percent of predicted, n=72) 28.0 (SD 15.9, range 3–95)
6 min walking test (n=75, in meters) 236 (SD 102.1, range 0–450)
St. George’s Respiratory Questionnaire (SGRQ) (n=76) 64.4 (SD 12.9, range 38–98)
COPD GOLD stage III 31 (35.2%)
COPD GOLD stage IV 57 (64.8%)
Abbreviations: FEV1%, forced expiratory volume in 1 second (percent of predicted); TLC, total lung capacity (percent of predicted); DLCO%, diffusing capacity of the lung
for carbon monoxide (percent of predicted); RV%, residual volume (percent of predicted); pre/post BS, before and after application of bronchodilators; FVC, functional vital
capacity; COPD, chronic obstructive pulmonary disease, SD, standard deviation.
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Distribution of HAV and LAV
The mean HAV, as determined with quantitative CT ana-
lysis, were 7.7% (SD 1.5) in inspiration and 10.5% (SD
3.3) in expiration (Figure 1, Table 2). In peripheral lung
volumes, extracted from scans acquired in full expiratory
breathhold, HAV accounted for up to 30.8% of all lung
parenchyma voxels in some patients. Much higher percen-
tages of all evaluated lung volumes showed attenuations
below of −950 HU, used as a threshold to deﬁne the LAV
(ie, emphysema index, EI): mean of 30.7% with SD of
8.6% for the whole lung in inspiratory breathhold and
24.5% with SD of 9.4% in expiratory breathhold. A max-
imum LAV of 62% was measured in central lung volumes
of one patient at full inspiration (for details see Table 2).
Impact of HAV on FEV1
There was no signiﬁcant correlation of HAV, used as a
quantitative correlate of ﬁbrotic changes of lung par-
enchyma, and FEV1% (p=0.786, see Table 3). In
whole lung volumes at full inspiration, only low
attenuation volumes (LAV) showed a signiﬁcant nega-
tive correlation with FEV1% (r=−0.309, R2=0.096,
p=0.008). The highest negative correlation of LAV
with FEV1% was identiﬁed in central volumes at
expiration (r=−0.377, p<0.001, R2=0.143 vs HAV with
p=0.376). There was no signiﬁcant correlation between
HAV and FEV1% in any of the investigated combina-
tions (central and peripheral volumes in inspiration and
expiration) (Table 3 and Figure 2).
Impact of HAV on FVC, RV, DLCO as
determined by quantitative CT analysis
Neither forced vital capacity (FVC) nor RV (each mea-
sured before and after application of a bronchodilator)
correlated with the extent of LAV and HAV as potential
correlates of emphysematous and ﬁbrotic lung tissue,
respectively (see Table 5).
Severely decreased DLCO% in our patient population
was associated with both larger HAV (p=0.045) and larger
LAV (p=0.001). No signiﬁcant correlation was detected
between the two parameters in terms of their impact on
DLCO% (p=0.573).
Impact of LAV and HAV on lung function
in subgroups with lowest and highest
degree of LAV
In order to conﬁrm these results, two subgroups with 1)


















































Figure 1 Distribution of HAV and LAV in full IN and full EX.
Note: Calculated LAV was always higher than HAV.
Abbreviations: TOT, whole lung; CORE, central lung areas; PEEL, peripheral lung areas; HAV, high attenuation volume; LAV, low attenuation volume; IN, full inspiration; EX,
full expiration.
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obstruction-dominant type (slightly higher than in study of
Lee et al 2010)29 and, 2), the highest possible percentage
of LAV (range from 35% to 51%, n=25) were analyzed. In
both subgroups, no statistical correlation between HAV
and FEV1% could be found. Only LAV correlated nega-
tively with FEV% in the subgroup with the lowest LAV
Table 2 Detailed distribution of HAV and LAV divided into respective percentage and peel/core subgroups
Total lung Core lung Peel lung
Mean distribution of HAV/LAV
%HAV inspiration 7.7 SD 1.5 6.0 SD 1.2 10.3 SD 2.0
%HAV expiration 10.5 SD 3.3 8.2 SD 2.7 13.4 SD 4.1
%LAV inspiration 30.7 SD 8.6 36.7 SD 10.1 21.7 SD 7.4
%LAV expiration 24.5 SD 9.4 29.8 SD 11.1 17.7 SD 8.7
Distribution of HAV
HAV ≤7% HAV =7–10 HAV >10
%HAV inspiration total n=28 (31.8%) n=54 (61.4%) n=6 (6.8%)
%HAV inspiration core n=76 (86.4%) n=11 (12.5%) n=1 (1.1%)
%HAV inspiration peel n=0 (0%) n=43 (48.9%) n=45 (51.1%)
%HAV expiration total n=5 (5.7%) n=41 (46.6%) n=42 (47.7%)
%HAV expiration core n=30 (34.1%) n=41 (46.6%) n=17 (19.3%)
%HAV expiration peel n=1 (1.1%) n=9 (10.2%) n=78 (88.6%)
Distribution of LAV
LAV <25% LAV =25–40% LAV >40%
%LAV inspiration total n=26 (29.6%) n=50 (56.8%) n=12 (13.6%)
%LAV inspiration core n=9 (10.2%) n=38 (43.2%) n=41 (46.6%)
%LAV inspiration peel n=56 (63.6%) n=31 (35.2%) n=1 (1.1%)
%LAV expiration total n=44 (50%) n=39 (44.3%) n=5 (5.7%)
%LAV expiration core n=32 (36.4%) n=44 (50%) n=12 (13.6%)
%LAV expiration peel n=71 (80.7%) n=16 (18.2%) n=1 (1.1%)
Note: Distribution of HAV- and LAV subgroups, peel deﬁned as volume within, core as volume without a subpleural margin of 2 cm.
Abbreviations: %LAV, percentage of low attenuation volume; %HAV, percentage of high attenuation volume.
Table 3 Results of multivariate and simple regression analysis before and after application of bronchodilators
Before use of bronchodilators (n=88) After use of bronchodilators (n=86)
Multivariate
analysis
R2 Simple regression Multivariate
analysis
R2 Simple regression
HAV LAV LAV and
FEV1%
p= HAV LAV LAV and
FEV1%
p=
FEV1% whole lung in
inspiration
0.786 0.008 0.096 −0.309 0.003 0.616 0.022 0.078 −0.208 0.009
FEV1% core lung in inspiration 0.744 0.017 0.104 −0.323 0.002 0.945 0.026 0.085 −0.291 0.006
FEV1% peel lung in inspiration 0.213 0.106 0.054 0.233 0.029 0.167 0.148 0.048 −0.218 0.044
FEV1% whole lung in
expiration
0.431 0.091 0.136 0.369 <0.001 0.052 0.196 0.132 −0.363 0.001
FEV1% core lung in expiration 0.376 0.015 0.143 0.377 <0.001 0.186 0.063 0.136 −0.377 <0.001
FEV1% peel lung in expiration 0.587 0.027 0.097 0.312 0.003 0.431 0.036 0.102 −0.320 0.003
Notes: Correlations of HAV and LAV with FEV1%. There is no signiﬁcant correlation (p<0.05) of HAV and FEV1% for any of the datasets.
Abbreviations: FEV1%, forced expiratory volume in 1 second (percent of predicted); LAV, percentage of low attenuation volume; HAV, percentage of high attenuation
volume; peel, peripheral lung (lung volume within a subpleural margin of 2 cm); core, central lung (lung volume without a subpleural margin of 2 cm).
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(p=0.025 in multivariate analysis, r=−0.419, R2=0.176,
p=0.037), see Table 3.
Impact of LAV and HAV on volume
difference in study subjects´ pulmonary
lobes with lowest and highest HAV
In another subgroup analysis (n=83; n=5 patients with
missing data of quantitative lobe-based analysis due to
technical problems), we determined the respective lobe
with the highest HAV (n=30/83 (36%) upper and middle
lobes, n=53/83 (63.4%) lower lobes) and lowest HAV
(n=58/83 (51.8%) upper and middle lobes, n=25/83
(30.1%) in lower lobes). Bivariate (Pearson correlation)
and simple linear regression analyses of both HAV and
LAV correlated with volume difference between inspira-
tion and expiration showed a signiﬁcantly positive
correlation between LAV and the volume difference only
for the respective lobe with the lowest HAV (r=0.313,
R2=0.098, p=0.004). In the lobe with the highest HAV
content, LAV did not correlate signiﬁcantly with the
volume difference (see Table 4).
Impact of bronchodilators on quantitative
CT results
In this study, the use of a fast-acting bronchodilator before
lung function tests had no signiﬁcant impact on the results
of quantitative CT analysis (Tables 3 and 5).
Discussion
Unspeciﬁc ﬁbrotic changes of lung parenchyma are a
frequent incidental ﬁnding in CT scans of patients with
COPD and severe pulmonary emphysema. Our results
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Figure 2 Correlation of HAV andLAV with forced expiratory volume in 1 second, percent of predicted (FEV1%) in different lung volumes and breathhold series. All lung
function tests were performed without prior bronchospasmolysis. In full expiration, more than 88% of the lung parenchyma in peripheral lung areas accounted for HAV
(second row on the right). Even in this situation, solely LAV showed a signiﬁcant negative correlation with FEV1% and HAV did not (LAV: r=−0.312, R2=0.097, p=0.027; HAV:
p=0.587).
Abbreviations: Peel, peripheral volumes of lung tissue; Core, central volumes of lung tissue; LAV, percentage of low attenuation volume; HAV, percentage of high
attenuation volume; IN, full inspiration; EX, full expiration.
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by the magnitude of HAV in CT scans, probably have no
statistically signiﬁcant effect on pulmonary function in
contrast to LAV. To the best of our knowledge, this is the
ﬁrst study to evaluate the possible functional effects of
incidental ﬁbrosis in patients with COPD GOLD stage III
or IV.
A LAV-threshold of −950 HU, as used in our study, is
most commonly used for quantitative CT estimation of
emphysema, yielding a good balance between sensitivity
and speciﬁcity.12,14,30–32 In our cohort of patients with
pulmonary emphysema, mean LAV was 30.7% (SD 8.6),
which is expectably much higher than in a group of
healthy suspects. LAV of 2.6–4.5% are reported to be
normal for individuals 30–70 years of age, based on
regression analysis.14
Only few studies have examined correlations
between HAV (also referred to as HAA) and reproduci-
ble clinical parameters yet. We used HAV as a parameter
potentially representing ﬁbrotic changes of lung par-
enchyma, as it has already been used in a number of
recent studies.22,26,33 With a mean of 7.7% and SD of
1.5% on inspiratory scans (expiratory scans 10.5%, SD
3.3) of the entire lung parenchyma, HAV in our cohort
of COPD patients was slightly higher, than the values
reported previously for an average population. The
6,813 participants of the MESA study (Multi-Ethnic
Study of Atherosclerosis) for example were evaluated
with a mean HAV of only 5.1±3.1% (1.2–48.9%). In this
study, HAV were deﬁned by a range of −250 to −600
HU and only parts of the lung were examined because
cardiac CT scans were used for analysis.33 Other studies
referring to interstitial lung disease used alternative
thresholds, for example, −700 to −500 HU, for predo-
minant ﬁbrotic interstitial lung disease and identiﬁed
negative correlation with diffusing capacity of the
lungs for carbon monoxide (DLCO).26
Using an attenuation range of 0 to −700 HU, Matsuoka
et al (2015) found the highest correlation to exist between
ﬁbrosis (“interstitial lung disease volume”) and DLCO.22
In another study conducted in 2016, Matsuoka et al, cor-
related different pathological lesions (subtypes of ﬁbrotic
patterns such as ground-glass opacity, reticulation, or hon-
eycombing) with different attenuation values to determine
their impact on pulmonary function.24 Compared to these
recent ﬁndings in patients diagnosed with CPFE, where up
to 17.0 SD 5.7% of the whole lung parenchyma showed
higher attenuation at a lower threshold of −700 HU, HAV
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Of note, HAV is not speciﬁc for ﬁbrotic changes and
might also represent bronchial walls (subclinical) infection
and dystelectasis due to collapsed air spaces, especially in
expiratory breathhold scans or in patients with solid malig-
nant lesions. Therefore, in some patients of our study,
pulmonary edema due to heart failure, airway inﬂamma-
tion or bronchiolitis might have contributed to the magni-
tude of HAV. Because we excluded all patients with
(clinically or histopathologically) conﬁrmed diagnosis of
IPF (Interstitial pulmonary ﬁbrosis), NSIP, CPFE or acute
pulmonary infection, it is unlikely that these diseases sig-
niﬁcantly contributed to our results. To avoid confounding
factors such as consolidation areas like partial atelectasis,
major scars, effusion, or solid tumors objectively, we also
excluded these patients. Compared to previous studies, the
range of 0 to −700 HU was wide enough to capture all
potential patterns of ﬁbrosis, as described in recent
studies.22,24 We obtained consistent results during inspira-
tion and expiration as well as before and after administra-
tion of a bronchodilator (the smooth bronchial muscles
relax, which normally causes an increase of FEV),34 sug-
gesting that dystelectasis due to collapsed airways had no
measurable impact on the quantitative CT analysis in our
study. Nonetheless, residual confounding by undiagnosed
or low-grade stages of disease cannot be fully ruled out.
In our population, LAA measured approximately 2.5–4
times higher than HAA, meaning more voxels accounting
for these volumes (even in full expiration with partial
collapse of lung parenchyma). However, for some patients,
we calculated a HAV of up to 30.8%, especially in
peripheral areas. Although we found more areas with
high attenuation due to collapsed bronchioles/lung tissue
in expiration scans, there was no statistically signiﬁcant
impact of HAV on lung function. Results were consistent
between central and peripheral lung volumes or scans
acquired with and without the use of a fast-acting bronch-
odilator. In the case of clinical relevance, this could mean
that the use of bronchodilators could be dispensed with for
future studies. The results are supported by the fact that
even in subgroup analyses with study subjects including
particularly high and low percentage of LAV, only LAV
had a negative correlation with FEV1%. This means that
even with a relatively low proportion of LAV (<25%), the
inﬂuence of the emphysematous changes seems to over-
whelm that of the ﬁbrotic changes. As a result, the rele-
vance of CT-morphologically detectable, ﬁbrotic changes
in the interdisciplinary, clinical conference could be better
classiﬁed/relativized. In clinical practice, this could possi-
bly have an inﬂuence on therapy decision or give rise to
further, comparative intervention studies to improve
therapy.
In the second subgroup analysis, we show that at the
level of the pulmonary lobe our data indicates at least a
partial counterbalancing effect of HAV and LAV in
COPD, as described for CPFE or low-grade ﬁbrosis in
smokers.21,22 We found no counterbalancing effect of
HAV and LAV on the pulmonary function and attribute
it to the fact that the lung function represents an interac-
tion of all lung subdivisions (lobes, segments) and
bronchi involved in the gas exchange. This assumption
Table 5 Independent contributions of LAV and HAV
Variable Standardized regression in multivariate analysis p-values for covariables




















No correlation of LAV/HAV, p=0.573
Note: No correlation between LAV and HAV was found.
Abbreviations: FVC%, functional vital capacity (percent of predicted); RV%, residual volume (percent of predicted); DLCO%, diffusing capacity of the lung for carbon
monoxide (percent of predicted); LAV, percentage of low attenuation volume; HAV, percentage of high attenuation volume; pre/post BS, before and after application of
bronchodilators.
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is supported by the missing decline of vital capacity in
our patients. Higher degrees of ﬁbrosis typically result in
a decreased vital capacity, due to greater stiffness of lung
parenchyma and decreased pulmonary elastic recoil.35
Since it is not possible to determine the proportional
inﬂuence of separate pulmonary lobes or even segments
on lung function with any technique or software known
to us, correlation of HAV and LAV with the volume
difference in the respective lobe with particularly low
and high HAV was performed. It was found that with a
high proportion of HAV, there is no signiﬁcant correlation
with the volume difference. At low HAV in a pulmonary
lobe, however, the volume difference decreases very
much with increasing LAV (see Table 4 and Figure 3).
To what extent the inﬂuence of HAV on LAV on volume
difference then means a reduction of air trapping (airway
pathology) or elasticity (pathology of parenchyma) can
hardly be differentiated by quantitative CT analysis, in
our view. Our lobe-based results can be seen as an indi-
cator for a heterogeneous distribution of ﬁbrotic and
emphysematous patterns even from the level of pulmon-
ary lobes. Current data show impressively that even
within individual lobes different areas exist with HAV
and LAV and a distinct regional variability, furthermore
different sized LAV clusters seem to be inﬂuenced by
adjacent HAVs.36,37 In this regard, future studies on
interfaces between LAV and HAV or regional distribution
may be of interest for better understanding of pathophy-
siology. Nevertheless, from our point of view, the clinical
relevance and correlation with clinical parameters are
very important and should always be considered. Less
complex, maybe even lobe-related, analysis could be
beneﬁcial to the clinical applicability and acceptance of
quantitative CT analysis. It might improve already used
(partial resection, bronchoscopic lung volume reduction
coil, BLVR) or future therapy procedures.
As a last result, our data show a signiﬁcant negative
association of both LAV and HAV with reduced DLCO%,
also in our cohort of high-grade emphysema patients. In
fact, the interaction between LAV and HAV regarding this
parameter is not signiﬁcant (p=0.573), as already shown in
CPFE.38 Decrease of DLCO, regarded as a correlate of
impaired gas exchange, has been well recognized in
patients with CPFE.17,39 The reduction has been attributed
to reduced gas exchange in areas with combined emphy-
sema and ﬁbrosis. Recent ﬁndings in CPFE-patients even
indicate a more signiﬁcant impact of ﬁbrosis than emphy-
sema on lung function as reﬂected in DLCO.22
Apart from the intrinsic limits of retrospective studies,
there are several limitations to this study. First, the number
of patients is small. Second, a qualitative analysis of HAV
patterns was not performed, although we excluded patients
with acute pneumonia or relevant dystelectasis. Third, thin
section scans at 1.25 mm might have been too thin to
measure LAV with a threshold setting of −950 HU, as it
was reported that in thin CT sections noise and especially
emphysema is often overestimated.40 Matsuoka et al, used
sections of 2 mm for correlation of HAV patterns and PFT
in 2015 and 2016.24 Furthermore, up to the time they
underwent CT, our patients had no diagnosis of UIP or
other speciﬁc interstitial ﬁbrosis. A histopathological eva-
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Figure 3 Correlation of LAV with volume difference between ex- and inspiration in pulmonary lobes with the highest and lowest percentage of HAV, respectively. Only with a low
proportion of ﬁbrotic patterns low attenuation volumes seem to statistically signiﬁcantly reduce the volume difference (as a measure of elasticity or air trapping) in the affected lobe (see
right functional graph); LAV´s Pearson´s r=0.313, R2=0.098, p=0.0004; HAV: p=0.572). In pulmonary lobes with high HAV, no signiﬁcant correlation between LAV and the volume
difference could be demonstrated.On the contrary, the relationship seems to at least tend to be inverse (see left functional graph); LAV´s Pearson´s r=−0.112, R2=0.013, p=0.312; HAV:
p=0.836).
Abbreviations: LAV, percentage of low attenuation volume; HAV, percentage of high attenuation volume.
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The exclusion criteria, regarding patterns of pneumonia,
interstitial pulmonary ﬁbrosis, partial atelectasis or major
scars as well as NSIP or malignant lesions were applied
subjectively and may have biased the results.
Retrospective analysis of a study population is always
subject to selection bias.
Conclusion
Our results indicate, that in patients with COPD GOLD stage
III-IVemphysematous changes show a statistically signiﬁcant
negative correlation with pulmonary function (ie FEV1%),
whereas incidental unspeciﬁc ﬁbrotic changes (HAV) of lung
parenchyma do not. Additionally, neither LAV nor HAV cor-
related signiﬁcantly with RV or forced vital capacity. Use of
bronchodilators prior to pulmonary function tests has no
impact on these results. Presence of both LAV and HAV is
signiﬁcantly correlated with reduced DLCO%, whereas the
interaction between LAVand HAV is not signiﬁcant.
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